tbuckley/cabot-search huggingface dataset:
Abstract 4861: The role of histone deacetylases (HDACs) in XPC gene silencing and bladder cancer development
Authors: Gan Wang, Lily Wang, Xiaoxin S. Xu
Journal: Cancer Research (2010)

Abstract The role of histone deacetylases (HDACs) in XPC gene silencing and bladder cancer development Xiaoxin S. Xu, Le Wang, and Gan Wang Institute of Environmental Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48202 Bladder cancer is one of the most common malignancies and causes hundreds thousands of death worldwide each year. Bladder cancer is strongly associated with exposure to environmental carcinogens. It is believed that DNA damage generated by environmental carcinogens and their metabolites causes development of bladder cancer. Nucleotide excision repair (NER) is the major DNA repair pathway for repairing bulk DNA damage generated by most environmental carcinogens and XPC is a DNA damage recognition protein required for initiation of the NER process. Recent studies demonstrate reduced levels of XPC protein in tumors for a majority of bladder cancer patients. In this work we investigated the role of histone deacetylases (HDACs) in XPC gene silencing and bladder cancer development. The results of our HDAC inhibitor study revealed that the treatment of HTB4 and HTB9 bladder cancer cells with HDAC inhibitor valproic acid (VPA) caused an increase in transcription of the XPC gene in these cells. The results of our chromatin immunoprecipitation (ChIP) studies indicated that the VPA treatment caused increased bindings of both CREB1 and Sp1 transcription factors at the promoter of XPC gene for both HTB4 and HTB9 cells. The results of our immunohistochemistry (IHC) staining studies further revealed a strong correlation between the presence of HDAC4 and the occurrence of bladder tumors. In addition, the results of our caspase 3 activation studies demonstrated that the prior treatment with VPA increased the anticancer drug cisplatin-induced activation of caspase 3 in both HTB4 and HTB9 cells. All these results suggest that the HDACs negatively regulate transcription of the XPC gene in bladder cancer cells and contribute to the development of bladder cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4861.
THU0435 Performance of the Usual Clinical and Biological Signs for the Diagnosis of Septic Arthritis
Authors: M. Couderc, S. Mathieu, B. Pereira, J. Schmidt, O. Lesens, R. Bonnet, F. Al juhani, M. Vayssade, B. Glace, A. Tournadre, S. Malochet-guinamant, M. Soubrier, J.-J. Dubost
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To study the sensibility (Se) and specificity (Sp) of clinical and biological signs for the diagnosis of septic arthritis (SA). <h3>Methods</h3> This prospective study included all adult patients with a suspicion of SA seen in the emergency department or rheumatology service at the University Hospital of Clermont-Ferrand during a period of 18 months. The sensibility and specificity of the clinical and biological signs for the diagnosis of SA were calculated. A univariate analysis followed by a logistic regression analysis for SA diagnosis was conducted. <h3>Results</h3> In total, 105 patients with a suspected SA were included, 38 (36%) presenting with SA (29 with a bacteriologically documented SA). In univariate analysis, chills (Se 39%; Sp 82%, p=0.015) but not fever (Se 53%; Sp 53%, p=0.6), a slow onset duration (Se 54%; Sp 72%, p=0.04), local redness (Se 53%, Sp 72%, p=0.01), as well as an infection entry-site (Se 7%; Sp 54%, p=0.01) were found most often in the SA cases. Microcrystalline antecedents (Se 5%, Sp 72%, 95% CI 0-0.6) and involvement of the knee were more frequent in non-septic arthritis (non-SA) cases. An erythrocyte sedimentation rate (ESR) &gt;50 mm (Se 72%; Sp 60%, p=0.005), a C-reactive protein level &gt;100mg/L (Se 58%; Sp 66%, p=0.019) and, above all, suggestive radiological signs (Se 30%; Sp 95%, p=0.001) were more frequent in the SA cases. The clear (Se 0; Sp 81%, p=0.007) and purulent (Se 57%, Sp 88, p&lt;0.001) aspect of synovial fluid allowed for the differentiation between SA and non-SA, as well as the synovial fluid white blood cell (WBC)&gt;50000/μL (Se 57%; Sp 82%, p&lt;0.001) and percentage of polymorphonuclear &gt;90% (Se 42%; Sp 82%, p=0.02), but not the presence of microcrystals (Se 24%, Sp 58% p=0.09). In multivariate analysis, only chills (OR=4.1, 95% CI: 1.4-12.2), microcrystalline antecedents (OR=0.08, 95% CI: 0.01-0.5), and radiological signs (OR=11, 95% CI: 2.4-50.1) remained significant. The parameters chills, microcrystalline antecedents, infection entry-site, risk factors for SA, the aspect and cellularity of synovial fluid, and radiological signs permitted the elaboration of two logistic regression models for the diagnosis of SA (AUC: 0.85 and 0.87). <h3>Conclusions</h3> No clinical or biological (excluding bacteriological) sign, taken alone, is conclusive for the differentiation between SA and non-SA pathology, but the association of several signs, notably chills, microcrystalline antecedents, radiological signs of SA, and the aspect and cellularity of joint liquid may be conclusive. <h3>Disclosure of Interest</h3> None Declared
AB0683 Prevalence of the Metabolic Syndrome According to Various Definitions in Patients with Ankylosing Spondylitis
Authors: C. Papagoras, T.E. Markatseli, H.J. Milionis, E. Kaltsonoudis, P.V. Voulgari, A.A. Drosos
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> There is evidence that inflammatory joint disease is associated with increased cardiovascular risk. Systemic inflammation and reduced physical activity may be involved through changes in insulin sensitivity and obesity, thus allowing for the emergence of the metabolic syndrome. <h3>Objectives</h3> To study the prevalence and components of the metabolic syndrome in patients with ankylosing spondylitis (AS) in comparison with healthy controls. <h3>Methods</h3> Non-diabetic patients with AS followed at a single center and age- and sex- matched healthy controls were included in the study. The metabolic syndrome was defined according to the National Cholesterol Education Program: Adult Treatment Panel III (NCEP:ATP III), the American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI), the International Diabetes Federation (IDF) and the Joint Interim Statement (JIS) criteria<sup>1</sup>. <h3>Results</h3> Seventy-six AS patients and 63 healthy controls were included. Patients were more often smokers (p&lt;0.001) and had significantly lower HDL (p=0.002) and triglyceride levels (p=0.018) than controls. According to the NCEP:ATP III, AHA/NHLBI, IDF and the JIS criteria respectively, 9.2%, 13.2%, 22.4% and 23.7 of AS patients had the metabolic syndrome compared to 6.3%, 9.5%, 19% and 19% of healthy controls (p=NS between patients and controls for all metabolic syndrome definitions). Focusing on the individual metabolic syndrome criteria, no criterion was fulfilled significantly more often by AS patients compared to controls, although the “low HDL” criterion reached near-significance (p=0.083). <h3>Conclusions</h3> The proportion of AS patients with the metabolic syndrome varies widely according to the definition used. However, the metabolic syndrome does not seem to be more prevalent in the AS patients compared to healthy controls despite having lower HDL cholesterol. <h3>References</h3> Circulation. 2009;120:1640-5. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3141
Abstract 959: ERα1 represses breast cancer EMT by inhibiting EGFR-mediated downregulation of E-cadherin
Authors: Christoforos Thomas, Gayani Rajapaksa, Fotis Nikolos, Ruixin Hao, Anne Katchy, Maria Bondesson, Savitri Krishnamurty, Francisco Esteva, Jan-Ake Gustafsson
Journal: Cancer Research (2012)

Abstract Although epithelial to mesenchymal transition (EMT) is associated with specific breast cancer phenotypes, such as the basal-like and claudin-low tumors, there is a lack of validated markers, which can distinguish tumors with poor clinical outcome and high metastatic potential. Estrogen receptor beta (ERα) has been shown to regulate invasion in prostate cancer. However, it is still unclear if ERα by influencing invasion can predict metastasis in breast cancer. Here we show that wild-type ERα (ERα1) inhibits EMT and invasion in basal-like breast cancer cells when they grow either in vitro or in vivo in zebrafish. This correlates with an ERα1-mediated upregulation of miR-200a, miR-200b and miR-429 and the subsequent repression ZEB1 and SIP1, which results in increased expression of E-cadherin. Downregulation of the basal marker EGFR was found to be involved in the ERα1-mediated mesenchymal to epithelial transition since induction of EGFR expression or treatment with EGF abolished the ability of ERα1 to sustain the epithelial phenotype. This inverse correlation of ERα1 with EGFR and its positive association with epithelial markers was additionally observed in breast cancer specimens. These results strengthen the association of ERα1 with the regulation of EMT and propose the receptor as potential crucial marker in predicting survival and metastasis in breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 959. doi:1538-7445.AM2012-959
THE INFLUENCE OF AGEING ON MICROVASCULAR RESISTANCE AND ITS EFFECT ON FFR AND CFR DISCORDANCE
Authors: Martijn van Lavieren, Mauro Echavarria-Pinto, Tim van de Hoef, Martijn Meuwissen, Patrick Serruys, Javier Escaned, Jan Piek
Journal: Journal of the American College of Cardiology (2015)
Abstract P3-04-08: Expression of hormone-responsive genes in benign breast tissue varies with menstrual cycle phase and menopausal status
Authors: H Hu, J Wang, O Lee, A Shidfar, S Iyer, D Ivancic, RT Chatterton, V Stearns, S Sukumar, SA Khan
Journal: Cancer Research (2012)

Abstract Background: The expression of many genes is known to be regulated by ambient hormone levels. In a preliminary study of random fine-needle aspirate (rFNA) samples from benign breast tissue, we found several genes that were highly correlated with the serum levels of progesterone (P4) and estradiol (E2). We now present data to further validate these genes as markers of menstrual cycle phase (MCP) and menopausal status (MPS) in benign breast tissue which may allow retrospective classification of archived breast samples with respect to MCP and MPS at the time of sampling. Methods: 240 rFNA samples from healthy women with recorded hormonal data at the time of sampling were analyzed. We divided these subjects by menstrual cycle phase (MCP) and menopausal status (MPS): 41 early follicular: (low circulating E2 and P4); 48 mid-cycle (high E2 and low P4); 31 luteal (moderate E2 and high P4). 120 post-menopausal (low E2 and low P4). 100 ng of RNA from rFNA samples of the breast was reverse transcribed. Amplicons of interest were linearly amplified to 14 cycles for 35 genes related to hormone responsiveness. qPCR reactions were carried out using the TaqMan OpenArray (Applied Biosystems). For each gene of interest, expression levels were normalized to the average expression of GAPDH. Gene expression difference between groups were conducted using the Mann-Whitney Test. P-values from gene expression difference were adjusted via the Benjamini-Hochberg (1995) approach. Results: The mean value of TNFSF11 expression level was 13.19 fold higher in luteal phase subjects than in post-menopausal subjects (p = 0.0003) where there was also the biggest difference of serum P4 level between groups. The expression of DIO2 and MYBPC1 was also significantly higher in luteal phase group than in the post-menopausal group (p = 0.005, p = 0.02, respectively). These 3 genes also demonstrated a higher expression pattern in luteal phase than mid-cycle and follicular phase but analysis is still ongoing. All comparisons between these groups will be presented at the meeting. Conclusion: The expression levels of TNFSF11, DIO2 and MYBPC1 vary with MCP and MPS. These hormone-responsive genes are candidate MCP classifiers which could be applied to archived breast samples to assess whether biomarkers of breast cancer risk are stable across the menstrual cycle, since MCP and MPS variation is likely an important source of biological noise in studies of archived breast biopsy material. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-04-08.
EFFICACY OF CATHETER ABLATION FOR VENTRICULAR ARRHYTHMIAS: A SYSTEMATIC REVIEW
Authors: Wael Alqarawi, H. Mia, P.B. Nery, M.M. Sadek, C.J. Redpath, D.H. Birnie, A. Szczotka, Girish Nair
Journal: Journal of the American College of Cardiology (2016)
Somatostatin Receptor Scintigraphy in a Patient With an Epigastric Mass and Multiple Liver Metastases
Authors: STEFANO FANTI, BARTOLOMEO BELLANOVA, ARTURO CHITI, ANNADINA ROMEO, ANGELA PETRONELLI, ACHILLE PANETTA, ANDREA MARTONI, FRANCO BERTONI, EMILIO BOMBARDIERI, NINO MONETTI
Journal: Clinical Nuclear Medicine (1997)

A patient with an epigastric mass and multiple liver metastases with a histopathologic diagnosis of adenocarcinoma was treated with combined chemohormonal therapy. She had a poor response, despite intense and repeated treatment. Somatostatin receptor scintigraphy with In-111 pentetreotide demonstrated the presence of somatostatin receptors in the primary lesion and in the liver metastasis, suggesting the tumor was of neuroendocrine nature. This finding led to a sudden change in treatment as a result of the beneficial use of octreotide, and to a revision in the diagnosis with pathologic recognition of a carcinoid. This case underlines the clinical impact of somatostatin receptor scintigraphy in patient management by providing information on the somatostatin receptor status of the tumor.
Abstract 4137: An improved assay system for cell migration and invasion.
Authors: Jeff Partridge, Stephen Rimsa, Paula Flaherty
Journal: Cancer Research (2013)

Abstract In vitro cell migration and invasion assays are frequently used as model systems for quantifying the directed movement of cells towards a chemoattractant stimulus, or to measure how a particular drug, antibody or extra cellular matrix (ECM) coating affects that movement. Analysis of this movement is often accomplished through the use of visual methods that are either time-consuming, labor-intensive, or subjective. To address these issues, an improved fluorescence blocking version of the Boyden chamber was developed. As cells migrate or invade through a unique fluorescence blocking microporous membrane, they can be detected using a bottom-reading spectrofluorometer or fluorescence microscope. Cells remaining in the upper chamber of the insert are shielded from this detection, allowing for quantitation of cell numbers in a homogeneous assay system. The technology blocks ≥ 98% transmission of light from 360 - 690 nm as measured by transmission spectrophotometry, and improvements have been made over previous embodiments such that &amp;gt;50% more light in the range of 360 - 490 nm is blocked. These enhancements now permit the use of the blue fluorescent Hoechst dyes and DAPI for direct cell enumeration and multiplexing. Functional applications of this technology were demonstrated in several well-established assays: endpoint staining in a model tumor invasion system yielded a Z’-factor &amp;gt;0.5; real-time chemotaxis of monocytes demonstrated a peak signal between 25-35 minutes; and migration of human endothelial cells to VEGF was demonstrated with high reproducibility (CV &amp;lt; 15%). Additionally, the measured IC50 values of chemotherapeutic compounds including paclitaxel and doxorubicin remained consistent with previously reported results. FluoroBlok™ cell culture inserts can efficiently be used for high-throughput cell migration studies, are automation friendly and yield highly reproducible results. Citation Format: Jeff Partridge, Stephen Rimsa, Paula Flaherty. An improved assay system for cell migration and invasion. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4137. doi:10.1158/1538-7445.AM2013-4137
Abstract 660: Inhibition of centrosomal clustering suppresses tumor growth <i>in vivo</i>
Authors: Marc S. Raab, Iris Breitkreutz, Blanka Leber, Ludmila Weitz, Patrick J. Hayden, Thomas O. Larsen, Mads H. Cllausen, Johannes Fruehauf, Felix Nissen, Walter Mier, Uwe Haberkorn, Klaus Podar, Anthony D. Ho, Hartmut Goldschmidt, Kenneth C. Anderson, Alwin Kraemer
Journal: Cancer Research (2011)

Abstract Tumor cells frequently contain multiple centrosomes, associated with the formation of multipolar mitotic spindles and chromosome segregation defects. To allow for bipolar mitotic division, supernumerary centrosomes are clustered into two functional spindle poles (centrosomal clustering). We recently described a phenotype-based small molecule screening strategy directed to induce tumor cells with supernumerary centrosomes to undergo multipolar mitoses, thereby resulting in apoptotic cell death (Rebacz et al., Cancer Res 2007; 67: 6342-6350). We here describe the novel small molecule GF-15, a derivative of griseofulvin and a potent inhibitor of centrosomal clustering, thereby inducing multipolar spindles followed by apoptosis. We tested more than 25 cancer cell lines from hematologic malignancies (including acute and chronic leukemias, lymphomas), solid tumors (including glioblastoma, colon, cervix, and pancreatic cancers) and a wide array of myeloma cell lines. We found mean inhibitory concentrations (IC50) for proliferation and survival in the range of 1-5μM GF-15, associated with activation of caspases 8, 9, and 3. As expected, tumor cell lines displaying only limited centrosomal aberrations or microsatellite instability were less sensitive to treatment with GF-15. Importantly, non-malignant cells without supernumerary centrosomes including PBMCs, immortalized hepatocytes, and bone marrow stromal cells, did not reach their IC50 even at 30μM GF-15. Specifically, cell cycle analysis of synchronized myeloma cells showed marked G2/M arrest, followed by a dramatic increase of the sub-G1 fraction, after treatment with GF-15. In addition, treatment with GF-15 was associated with inhibition of VEGF- and IGF1-triggered myeloma cell migration. Pharmakodynamic studies in vivo revealed rapid renal clearance of GF-15 and metabolites within 6 hours p.i. No acute or chronic toxicity was observed. Finally, both intraperitoneal and oral GF-15 treatment of murine xenograft models of human multiple myeloma resulted in tumor growth inhibition and significantly prolonged survival associated with significant increase of aberrant mitoses in vivo. Taken together, our results demonstrate the in vitro and in vivo anti-tumor efficacy of the first in class small molecule inhibitor of centrosomal clustering with specificity for tumor cells, and strongly support its clinical evaluation to improve patient outcome in both hematologic malignancies and solid tumors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 660. doi:10.1158/1538-7445.AM2011-660
Review 2 When you hear hoofbeats, don't think of zebras first
Authors: E. J. SEIFTER
Journal: JNCI Journal of the National Cancer Institute (1989)

Review 2 When you hear hoofbeats, don't think of zebras first Get access ERIC J. SEIFTER ERIC J. SEIFTER Johns Hopkins University611 Park Ave. Baltimore, MD 21201 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 19, 4 October 1989, Pages 1505–1506, https://doi.org/10.1093/jnci/81.19.1505-a Published: 04 October 1989
CORRELATION OF WALL SHEAR STRESS AND AXIAL PLAQUE STRESS BETWEEN MODELS DERIVED FROM CT AND OCT DATA
Authors: Gilwoo Choi, Kenzo Uzu, Takayoshi Toba, Hyun Jin Kim, Arjun Roy, Tran Nguyen, Leo Grady, Tomofumi Takaya, Shumpei Mori, Toshiro Shinke, Bon Kwon Koo, Charles Taylor, Hiromasa Otake
Journal: Journal of the American College of Cardiology (2016)
Percutaneous endoscopic gastrostomy using 10-cc syringe tubes for amyotrophic lateral sclerosis patients with limited mouth opening
Authors: S. Lee, H. Lee, D. Kim, K. Lee, O. Lee, H. Choi, B. Yoon, D. Jun, J. Hahm, Y. Joo
Journal: Endoscopy (2012)

Percutaneous endoscopic gastrostomy (PEG) is the most common method of delivering long-term enteral feeding to patients who are unable to take adequate nutrition by mouth [1]. We sometimes encounter patients for whom it is difficult to install the mouthpiece because of limitations of their mouth opening, such as in patients with neuromuscular disorders. In such cases we had tried transnasal insertion of the PEG, nasogastric feeding, or laparoscopic gastrostomy tube placement [2] [3] [4]. However, transoral insertion of PEG has many advantages over the other procedures [2] [3] [4] [5]. For that reason, we tested the feasibility of using a 10-cc syringe instead of a conventional mouthpiece during PEG in patients with limited mouth opening.